Stock BLCO BAUSCH + LOMB CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Bausch + Lomb Corporation

Equities

BLCO

CA0717051076

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-08 pm EDT 		5-day change 1st Jan Change
14.81 USD -0.60% Intraday chart for Bausch + Lomb Corporation +7.79% -13.19%
May. 06 Bausch + Lomb Shares Rise After Morgan Stanley Upgrade MT
May. 06 Morgan Stanley Upgrades Bausch + Lomb to Overweight From Equalweight, Raises Price Target to $18 From $16 MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company has insufficient levels of profitability.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
BAUSCH + LOMB CORPORATION Stock Bausch + Lomb Corporation
-13.19% 5.2B -
ABBOTT LABORATORIES Stock Abbott Laboratories
-4.66% 183B
C+
MEDTRONIC PLC Stock Medtronic plc
-1.01% 108B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.20% 67.51B
A
DEXCOM, INC. Stock DexCom, Inc.
+2.68% 50.67B
B-
CENCORA, INC. Stock Cencora, Inc.
+9.12% 44.7B
B-
HOYA CORPORATION Stock Hoya Corporation
+2.41% 40.95B
B+
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+4.13% 26.71B
A-
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+3.31% 26.8B
B
TERUMO CORPORATION Stock Terumo Corporation
+12.66% 24.62B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BLCO Stock
  4. Ratings Bausch + Lomb Corporation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW